ABSTRACT Summary: Drug absorption, distribution, metabolism and excretion (ADME) often involve interaction of a drug with specific proteins. Knowledge about these ADMEassociated proteins is important in facilitating the study of the molecular mechanism of disposition and individual response as well as therapeutic action of drugs. It is also useful in the development and testing of pharmacokinetics prediction tools. Several databases describing specific classes of ADME-associated proteins have appeared. A new database, ADME-associated proteins (ADME-AP), is introduced to provide comprehensive information about all classes of ADME-associated proteins described in the literature including physiological function of each protein, pharmacokinetic effect, ADME classification, direction and driving force of disposition, location and tissue distribution, substrates, synonyms, gene name and protein availability in other species. Cross-links to other databases are also provided to facilitate the access of information about the sequence, 3D structure, function, polymorphisms, genetic disorders, nomenclature, ligand binding properties and related literatures of each protein. ADME-AP currently contains entries for 321 proteins and 964 substrates.
INTRODUCTION
The efficacy of a drug is partly determined by its property of absorption, distribution, metabolism and excretion (ADME) inside human body (Caldwell et al., 1995; Eddershaw et al., 2000) . While passive diffusion plays an important role in pharmacokinetics of many drugs, drug ADME is also known to involve interaction of a drug or its metabolite with various proteins. For instance, drug metabolism is associated with interaction with specific metabolizing enzymes (Green et al., 1994) . In some cases, absorption or re-absorption of drugs is facilitated by drug binding to certain transporter proteins. The delivery of * To whom correspondence should be addressed. drugs to and away from the intended target sites may also involve the binding of drugs to carrier proteins, transporters, channels, or receptors (Zhang et al., 1998) . There are also situations in which delivery is opposed by drug binding to plasma proteins and intracellular binding proteins (Treuheit et al., 1992) .
Because of their essential roles in various processes of drug disposition, knowledge about these ADMEassociated proteins is important in facilitating the study of the molecular mechanism of individual events and complex collective processes of pharmacokinetics. Such knowledge is also useful in the development and testing of experimental techniques and computational methods for pharmacokinetics analysis and prediction (Eddershaw et al., 2000; Clark and Pickett, 2000; Norris et al., 2000; Chen and Zhi, 2001) .
Several specialized databases have appeared that provide information about certain aspects of specific class or group of ADME-associated proteins. These include human membrane transporter database (http://lab.digibench.net/transporter/), P450 (http: //medicine.iupui.edu/flockhart/) and P450 resource (http://p450.abc.hu/) databases. However, in some of these databases, the specific role of the proteins in ADME is not fully described. Moreover, there is a lack of information in these databases about certain ADME-related proteins such as carriers, receptors and certain types of metabolizing enzymes. Therefore, a publicly accessible database with comprehensive information about all known ADME-associated proteins is desired. ADME-Associated Proteins (ADME-AP) database is introduced with the aim to fulfill this purpose.
CLASSIFICATION OF ADME-ASSOCIATED PROTEINS
Based on their respective role of pharmacokinetics, ADME-associated proteins can be classified into four categories. Category A includes proteins involved in the absorption or re-absorption of drugs into systemic system. Category D includes proteins responsible for facilitating c Oxford University Press 2002 the distribution of drugs from the systemic system to the target sites or away from the target sites back to the systemic system. Certain plasma proteins and intracellular binding proteins may alter free drug concentration by acting as a drug storage depot. These proteins thus play a regulatory role in drug distribution and can be included in Category D. Based on their role in drug distribution, proteins in this category can be further divided into three groups D1, D2, and D3. D1 includes transporters capable of transporting chemicals across membranes of various tissue barriers from the systemic system into the target sites. D2 are responsible for transporting drugs back into the systemic system. D3 mainly functions as drug storage depot. Proteins in Category M are drug-metabolizing enzymes, which are further divided into two separate groups M1 and M2, according to whether the corresponding enzymatic reaction is Phase I or Phase II. Category E includes proteins facilitating the excretion or presystemic elimination of drugs. Some proteins belong to more than one category: e.g. P-glycoprotein both limits intestinal absorption and excludes drugs from the brain back to the blood (Kim et al., 1998) . It thus belongs to both Category E and D. For those proteins capable of transporting natural substrates without literature report of interaction with a drug, a postfix 'potential' is attached to their respective classification to indicate that their specific role in ADME is yet to be confirmed.
DATABASE STRUCTURE AND ACCESS
Proteins in ADME-AP are selected from a comprehensive search of available literatures including pharmacology textbooks, review articles and other relevant publications. Most entries are human proteins. As pharmacokinetics is often tested on animal models, the information about the availability of each entry in different species is included. ADME-AP has a web interface at http://xin.cz3.nus. edu.sg/group/admet/admet.asp, which is searchable by protein name, substrate/ligand name, ADME category, physiological function or SwissProt access number in the corresponding selection field. Searches involving any combination of these options or selection fields are also supported. The experimentally unconfirmed potential ADME-associated proteins can be accessed by selecting a potential ADME category name, e.g. potential A, in the class list.
Cross-links to other relevant databases are provided for access of further information about the properties of each protein which include sequence and function from SwissProt (http://tw.expasy.org/sprot), 3D structure from Protein Data Bank (PDB) (http://www.rcsb.org/pdb), possi- CONCLUSION AND FUTURE DEVELOPMENTS ADME-AP currently contains 321entries of proteins along with 964 substrates/ligands. With the rapid development of pharmacokinetics, more information about ADME-associated proteins will become available. Moreover, progress in the study of proteomics and pathways related to ADME-associated proteins will further facilitate our understanding of the mechanism of drug disposition. The relevant new information can be incorporated or the corresponding new databases can be cross-linked to ADME-AP to provide more comprehensive description about ADME-associated proteins. This database is to be updated frequently, information regarding newly identified ADME-associated proteins and additional knowledge about function of related proteins will be added. For such a purpose, a data submission interface is included in the database.
